FDA Grants Priority Review for Gedatolisib NDA, Sets July PDUFA Date; Q4 Losses Increase

summarizeSummary

Celcuity announced that the FDA granted Priority Review for its gedatolisib NDA with a PDUFA goal date of July 17, 2026, alongside reporting increased Q4 and full-year 2025 net losses, though with a cash runway through 2027.

check_boxKey Events

• FDA Grants Priority Review

  The FDA accepted Celcuity's New Drug Application (NDA) for gedatolisib in HR+/HER2- PIK3CA WT advanced breast cancer and granted Priority Review, setting a Prescription Drug User Fee Act (PDUFA) goal date of July 17, 2026.

• Positive Phase 3 Data Published

  Efficacy and safety results from the PIK3CA WT cohort of the Phase 3 VIKTORIA-1 study were published in the Journal of Clinical Oncology, demonstrating significant improvements in progression-free survival.

• Increased Net Loss

  The company reported a net loss of $51.0 million ($0.97 per share) for the fourth quarter of 2025, compared to $36.7 million ($0.85 per share) in the prior-year period, driven by increased operating expenses.

• Solid Cash Runway

  Celcuity ended fiscal year 2025 with $441.5 million in cash, cash equivalents, and short-term investments, which are expected to finance operations through 2027.

auto_awesomeAnalysis

The FDA's decision to grant Priority Review for gedatolisib's New Drug Application (NDA) is a highly significant positive development for Celcuity, accelerating the potential market entry of its lead therapeutic candidate. This, coupled with the positive Phase 3 VIKTORIA-1 study results published in a prestigious journal, substantially de-risks the drug's path to commercialization. While the company reported increased net losses and cash burn for Q4 and full-year 2025, the strong cash position, expected to finance operations through 2027, provides a solid runway to navigate the commercial launch phase. Investors should monitor the upcoming PDUFA date and the topline results from the PIK3CA mutant cohort in Q2 2026.